| Abbott (23) |  |
| Amgen (10) | |
| Astra-merck (6) | |
| Bayer (41) | |
| Boehringer-ingelheim (1) | |
| Bristol-myers-squibb (5) | |
| Dupont-merck (14) | |
| Eli lilly (5) | |
| Genentech (5) | |
| Genzyme (5) | |
| Glaxosmithkline (26) | |
| Hoechst-marion-roussel (4) | |
| Pasteur-merieux (8) | |
| Pfizer (22) | |
| Pharmaceutical industry (36) | |
| Pharmaceutical laboratory (1) | |
| Pharmacyclics (1) | |
| Roche pharmaceuticals (16) | |
| Sanofi-aventis (6) | |
| Stallergenes (1) | |
| Whitehall laboratories (3) | |
Eli lilly abandoned development of its osteoporosis drug arzoxifene, after results from an advanced clinical trial suggested it did not offer sufficient benefit over currently available treatments.
Glaxosmithkline, Merck and Eli lilly already publicly report physician payments; this will be mandatory from 2013, under US health-care reform law.
2011 墉 takes place at the UN headquarters in New york. go. nature. com/potx5i Number crunch 18%The number of health advocacy groups receiving funding from Eli lilly in the first
Other blockbusters due to come off patent include Sanofi-aventis's anti-clotting drug Plavix (clopidogrel) and Eli lilly's schizophrenia drug Zyprexa (olanzapine.
) Alzheimer s retest Eli lilly, a pharmaceutical company based in Indianapolis, Indiana, announced on 12 Â July that it will focus on patients with mild Alzheimer s disease in a forthcoming clinical trial of the drug solanezumab.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011